{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T12:31:00Z","timestamp":1787056260338,"version":"build-2736575974"},"reference-count":22,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2026,8,4]]},"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>Dermatomyositis (DM) is an idiopathic inflammatory myopathy with cutaneous and systemic manifestations influenced by autoantibody profiles. We report a rare case of anti-nuclear matrix protein 2 (anti-NXP2)-antibody-positive DM in a previously healthy man in his 30s presenting with fulminant proximal muscle weakness, severe dysphagia requiring percutaneous endoscopic gastrostomy, massive anasarca (&gt;30\u2009kg fluid overload), respiratory failure requiring mechanical ventilation and tracheostomy, and characteristic cutaneous manifestations. MRI demonstrated diffuse myositis and elevated muscle enzymes with anti-NXP2 antibody positivity supporting the diagnosis. Treatment with pulse corticosteroids, intravenous immunoglobulin and subsequent azathioprine resulted in biochemical and clinical improvement, although the course was complicated by pulmonary embolism, pneumonia and gastrointestinal bleeding. Following prolonged immunosuppression and intensive multidisciplinary rehabilitation, the patient achieved substantial functional recovery. This case highlights the potential reversibility of even fulminant anti-NXP2-positive DM with timely aggressive treatment and rehabilitation.<\/jats:p>","DOI":"10.1136\/bcr-2026-273992","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T11:55:28Z","timestamp":1787054128000},"page":"e273992","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Fulminant anti-nuclear matrix protein 2 antibody-positive dermatomyositis with massive anasarca, bulbar involvement and respiratory failure: recovery after prolonged immunosuppression and rehabilitation"],"prefix":"10.1136","volume":"19","author":[{"given":"Saifudheen","family":"Faroog","sequence":"first","affiliation":[{"name":"Internal Medicine, NYC Health + Hospitals, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Martinez Ortega","sequence":"additional","affiliation":[{"name":"Internal Medicine, NYC Health + Hospitals, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talya","family":"Toledano","sequence":"additional","affiliation":[{"name":"Radiology, NYC Health + Hospitals, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharika Gopakumar","family":"Menon","sequence":"additional","affiliation":[{"name":"Rheumatology, NYC Health + Hospitals, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"2026081804551580000_19.8.e273992.1","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMra2415426","article-title":"Inflammatory Myopathies","volume":"394","author":"Allenbach","year":"2026","journal-title":"N Engl J Med"},{"key":"2026081804551580000_19.8.e273992.2","first-page":"247","article-title":"Interstitial lung disease in adult patients with anti-NXP2 antibody positivity: a multicentre 18-month follow-up study","volume":"41","author":"Yan","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"2026081804551580000_19.8.e273992.3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s12016-022-08922-4","article-title":"Autoantibody Markers of Increased Risk of Malignancy in Patients with Dermatomyositis","volume":"63","author":"Marz\u0119cka","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"2026081804551580000_19.8.e273992.4","doi-asserted-by":"crossref","DOI":"10.1186\/ar3704","article-title":"Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine","volume":"14","author":"Schiopu","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"2026081804551580000_19.8.e273992.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-01045-w"},{"key":"2026081804551580000_19.8.e273992.6","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003901","article-title":"Severe gastrointestinal involvements in patients with adult dermatomyositis with anti-NXP2 antibody","volume":"10","author":"Fu","year":"2024","journal-title":"RMD Open"},{"key":"2026081804551580000_19.8.e273992.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211468"},{"key":"2026081804551580000_19.8.e273992.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.4770"},{"key":"2026081804551580000_19.8.e273992.9","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S1474-4422(25)00233-9","article-title":"Advances in the classification and management of idiopathic inflammatory myopathies","volume":"24","author":"Raaphorst","year":"2025","journal-title":"Lancet Neurol"},{"key":"2026081804551580000_19.8.e273992.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0250-9"},{"key":"2026081804551580000_19.8.e273992.11","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1212\/cont.0000000000001611","article-title":"A Pattern Recognition Approach to Myopathy","volume":"31","author":"Milone","year":"2025","journal-title":"Continuum (Minneap Minn)"},{"key":"2026081804551580000_19.8.e273992.12","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol"},{"key":"2026081804551580000_19.8.e273992.13","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/535738","article-title":"Epstein-Barr virus in systemic autoimmune diseases","volume":"2013","author":"Draborg","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"2026081804551580000_19.8.e273992.14","doi-asserted-by":"crossref","DOI":"10.3390\/v13020260","article-title":"Human Cytomegalovirus and Autoimmune Diseases: Where Are We?","volume":"13","author":"Gugliesi","year":"2021","journal-title":"Viruses"},{"key":"2026081804551580000_19.8.e273992.15","doi-asserted-by":"crossref","unstructured":"Huang L , Zhu W , Ye Y , et al . Association of Cytomegalovirus Infection With Anti-MDA5 Antibody-Positive Dermatomyositis: A Prospective Cohort Study. Front Med 2021;8. doi:10.3389\/fmed.2021.740154","DOI":"10.3389\/fmed.2021.740154"},{"key":"2026081804551580000_19.8.e273992.16","doi-asserted-by":"crossref","first-page":"104849","DOI":"10.1016\/j.jcv.2021.104849","article-title":"Subclinical CMV viremia is associated with increased nosocomial infections and prolonged hospitalization in patients with systemic autoimmune diseases","volume":"140","author":"Maksimowicz-McKinnon","year":"2021","journal-title":"J Clin Virol"},{"key":"2026081804551580000_19.8.e273992.17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/ara.ara_27_24","article-title":"Cytomegalovirus in Autoimmune Disease: Insights and Implications","volume":"5","author":"Baliga","year":"2025","journal-title":"Ann Rheumatol Autoimmun"},{"key":"2026081804551580000_19.8.e273992.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117912"},{"key":"2026081804551580000_19.8.e273992.19","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.944564","article-title":"Pharmacological Strategies in Dermatomyositis: Current Treatments and Future Directions","volume":"30","author":"Guo","year":"2024","journal-title":"Med Sci Monit"},{"key":"2026081804551580000_19.8.e273992.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.37754"},{"key":"2026081804551580000_19.8.e273992.21","article-title":"Non-targeted immunosuppressive and immunomodulatory therapies for idiopathic inflammatory myopathies","volume":"8","author":"Raaphorst","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"2026081804551580000_19.8.e273992.22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154441","article-title":"Dermatomyositis and Polymyositis in the Intensive Care Unit: A Single-Center Retrospective Cohort Study of 102 Patients","volume":"11","author":"Peng","year":"2016","journal-title":"PLoS One"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2026-273992","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T11:55:31Z","timestamp":1787054131000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2026-273992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":22,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,18]]},"published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1136\/bcr-2026-273992"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2026-273992","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}